Literature DB >> 19195729

Higher serum C-reactive protein concentration and hypoalbuminemia are poor prognostic indicators in patients with esophageal cancer undergoing radiotherapy.

Chang-Yu Wang1, Ming-Jang Hsieh, Yi-Chun Chiu, Shau-Hsuan Li, Hurng-Wern Huang, Fu-Min Fang, Yu-Jie Huang.   

Abstract

BACKGROUND AND
PURPOSE: We evaluate if C-reactive protein (CRP) is an objective biomarker of esophageal cancer in patients undergoing radiotherapy.
MATERIALS AND METHODS: Between November 2002 and July 2007, 123 patients undergoing radiotherapy for newly diagnosed esophageal cancer were enrolled. Serum CRP concentration was measured before the initiation of treatment. The relationship between serum CRP levels and other relevant variables such as body mass index, white blood cell count, platelet count, bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), cholesterol, hemoglobin, and albumin levels was also analyzed.
RESULTS: Eighty-one patients of the 123 patients enrolled (65.9%) had elevated CRP levels (5mg/L). The 2-year survival for patients with CRP 5mg/L was 7.8% compared to 78.4% for patients with CRP <5mg/L. Hypoalbuminemia (albumin <3.5g/dL) was also related to shorter survival using univariate analysis. Multivariate analysis demonstrated that only higher serum CRP concentration and hypoalbuminemia were independent prognostic indicators for survival of patients with esophageal cancer.
CONCLUSIONS: Pretreatment serum levels of CRP and albumin are objective, easily measurable biomarkers which can be used in combination with conventional staging to accurately predict survival in patients with esophageal cancer treated with radiotherapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19195729     DOI: 10.1016/j.radonc.2009.01.002

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  38 in total

1.  Impact of change in serum albumin level during and after chemoradiotherapy in patients with locally advanced esophageal cancer.

Authors:  Kazuya Takeda; Rei Umezawa; Noriyoshi Takahashi; Haruo Matsushita; Maiko Kozumi; Yojiro Ishikawa; Takaya Yamamoto; Ken Takeda; Keiichi Jingu
Journal:  Esophagus       Date:  2018-03-26       Impact factor: 4.230

2.  Prognostic value of pre-treatment maximum standardized uptake value and CRP in radiotherapy of esophageal cancer.

Authors:  Haruka Jinnouchi; Hideomi Yamashita; Tomoki Kiritoshi; Yosuke Miki; Atsuto Katano; Keiichi Nakagawa; Osamu Abe
Journal:  Mol Clin Oncol       Date:  2021-05-25

3.  Changes of acute-phase protein levels in the serum of lung cancer patients following radiotherapy.

Authors:  Tolia G Maria; Kouloulias E Vasileios; Pantelakos S Panagiotis; Syrigos N Kostas
Journal:  Int J Clin Exp Med       Date:  2012-11-18

4.  Prognostic value of an inflammation-based score in patients undergoing pre-operative chemotherapy followed by surgery for esophageal cancer.

Authors:  Hiroshi Miyata; Makoto Yamasaki; Yukinori Kurokawa; Shuji Takiguchi; Kiyokazu Nakajima; Yoshiyuki Fujiwara; Masaki Mori; Yuichiro Doki
Journal:  Exp Ther Med       Date:  2011-06-30       Impact factor: 2.447

5.  Hypoalbuminemia in children with cancer treated with chemotherapy.

Authors:  Thomas Williams McLean; Ryan Michael Stewart; Thomas Patrick Curley; Mark Young Dewsnup; Sydney Gillian Thomas; Thomas Bennett Russell; Janet Austin Tooze
Journal:  Pediatr Blood Cancer       Date:  2019-11-17       Impact factor: 3.167

6.  Comparative evaluation of serum C-reactive protein (CRP) levels in the different histological subtypes of esophageal cancer (squamous cell carcinoma and adenocarcinoma of esophagus).

Authors:  Marta Lukaszewicz-Zając; Barbara Mroczko; Mirosław Kozłowski; Jacek Nikliński; Jerzy Laudański; Maria Siewko; Maciej Szmitkowski
Journal:  J Clin Lab Anal       Date:  2012-02       Impact factor: 2.352

7.  What are the factors that predict outcome at relapse after previous esophagectomy and adjuvant therapy in high-risk esophageal cancer?

Authors:  E Yu; P Tai; R Malthaner; L Stitt; G Rodrigues; R Dar; B Yaremko; J Younus; M Sanatani; M Vincent; B Dingle; D Fortin; R Inculet
Journal:  Curr Oncol       Date:  2010-11       Impact factor: 3.677

8.  Serum albumin as a significant prognostic factor in patients with malignant pleural mesothelioma.

Authors:  Zhou-Hong Yao; Guang-Yan Tian; Shao-Xiang Yang; Yun-Yan Wan; Yan-Meng Kang; Qing-Hua Liu; Fei Yao; Dian-Jie Lin
Journal:  Tumour Biol       Date:  2014-04-15

9.  Risk factors of early recurrence within 6 months after esophagectomy following neoadjuvant chemotherapy for resectable advanced esophageal squamous cell carcinoma.

Authors:  Naoya Yoshida; Yoshifumi Baba; Hironobu Shigaki; Kazuto Harada; Masaaki Iwatsuki; Yasuo Sakamoto; Yuji Miyamoto; Junji Kurashige; Keisuke Kosumi; Ryuma Tokunaga; Masayuki Watanabe; Hideo Baba
Journal:  Int J Clin Oncol       Date:  2016-06-02       Impact factor: 3.402

10.  Prognostic value of the Glasgow Prognostic Score for glioblastoma multiforme patients treated with radiotherapy and temozolomide.

Authors:  Erkan Topkan; Ugur Selek; Yurday Ozdemir; Berna A Yildirim; Ozan C Guler; Fuat Ciner; Huseyin Mertsoylu; Kadir Tufan
Journal:  J Neurooncol       Date:  2018-04-25       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.